Yanki Yarman: My PhD Project Has Been Published in Blood!
Yanki Yarman, MD, Ph.D. Student at Sidney Kimmel Medical College, shared on LinkedIn:
”Hi everyone! I’m excited to share that my PhD project has been published in Blood, marking the culmination of four and a half years of work in a single major publication!!!
I’m deeply grateful to everyone involved, especially my labmates Xuefei Zhao and Hannah Thomson, and my PI, Peisong Ma, for their support and mentorship throughout this journey.
Our study links dysregulation of PAR1 signaling to abnormally high platelet activity caused by a platelet-specific GRK5 genetic variant (A>G at rs10886430), which affects approximately 5 million Americans. Importantly, we are the first to demonstrate a clinical association between GRK5 protein deficiency in GG individuals and increased prothrombotic risk, both ex vivo and in vivo, across arterial and venous thrombosis models.
Given the widespread use of genetic screening for thrombophilia in the clinical arena, we propose that this GRK5 variant be incorporated into existing genetic testing panels for patients presenting with venous thromboembolism or stroke at a younger age, particularly those with compounding risk factors.
For those interested in reading more about our study, you can find the PDF here.”
Article: Understanding how a highly prevalent GRK5 polymorphism affects platelets and enhances thrombotic risk
Authors: Yanki Yarman, Xuefei Zhao, Hyunsook Ahn, Hannah A Thomson, Amrita Sarkar, Tian Yuan, Meghan E. Roberts, Jeremy Wurtzel, Scott L Diamond, John J.G Tesmer, Deborah L French, Maurizio Tomaiuolo, Ernest Turro, William Astle, Lawrence E. Goldfinger, Steven E. McKenzie, Jeffrey Benovic, Timothy J. Stalker, Mortimer Poncz, Peisong Ma
Stay updated on all scientific advances with Hemostasis Today.
-
Mar 16, 2026, 17:12Cold-Stored vs Room-Temperature Platelets in Trauma-Induced Coagulopathy – JTH
-
Mar 16, 2026, 17:10Arturo Cesaro: First Meta-Analysis on the Vascular Protective Role of Semaglutide in PAD
-
Mar 16, 2026, 17:01Jeff Sternlicht: The Most Powerful Time to Lower Cholesterol Is Before Anyone Thinks You Need It
-
Mar 16, 2026, 16:14Siobhan Calafiore: Clinical Advantages of Apixaban Over Rivaroxaban in Reducing Bleeding Risk
-
Mar 16, 2026, 16:12Nuha El Sayed: Focused Summary of the 2026 ACC/AHA Guideline on Management of Dyslipidemia in Diabetes
-
Mar 16, 2026, 16:08Deepak Sudheendra: When a Vascular Looking Skin Pattern Isn’t Vascular
-
Mar 16, 2026, 16:06Surendra Karki։ Examining Blood Type and Coronary Heart Disease Risk in Australian Donors
-
Mar 16, 2026, 15:58Alan Nurden: Genome-Wide Analyses Unravel the Genetic Architecture of Coagulation and Fibrinolysis
-
Mar 16, 2026, 15:56Emmanuel J. Favaloro: Latest Publication from Sydney Centres on Heparin Therapy and Monitoring